Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nalak Das headshot

5 Top Value Picks to Counter Recent Stock Market Softness

by Nalak Das

The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.

Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

Kinjel Shah headshot

3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020

by Kinjel Shah

Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.

Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $106.58, moving +0.16% from the previous trading session.

Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.

Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study

by Zacks Equity Research

Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

Amicus Progresses on Pipeline Development Amid Competition

by Zacks Equity Research

Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.

Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta

by Zacks Equity Research

Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.

4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020

by Zacks Equity Research

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 2nd

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

All You Need to Know About Alexion (ALXN) Rating Upgrade to Strong Buy

by Zacks Equity Research

Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Alexion Pharmaceuticals (ALXN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Alexion Pharmaceuticals (ALXN) closed at $108.15, marking a +0.75% move from the previous day.

Ekta Bagri headshot

3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

by Ekta Bagri

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

Gilead (GILD) Partners With Eisai for RA Candidate in Japan

by Zacks Equity Research

Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.

Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance

by Zacks Equity Research

Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

Sumit Singh headshot

Create a Value-Based Portfolio With These 4 Low P/CF Stocks

by Sumit Singh

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.

Alexion Pharmaceuticals (ALXN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Alexion Pharmaceuticals (ALXN) closed at $110.46 in the latest trading session, marking a +0.65% move from the prior day.

Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ALXN) Outperforming Other Medical Stocks This Year?

Kinjel Shah headshot

5 Low Price-to-Book Value Stocks to Buy as 2020 Nears

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

ALXN vs. HZNP: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ALXN vs. HZNP: Which Stock Is the Better Value Option?

Ekta Bagri headshot

Biotech Stock Outlook: M&A Activity Retains Growth Streak

by Ekta Bagri

The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.

Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

by Zacks Equity Research

The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.